CA2686488A1 - Colored esmolol concentrate - Google Patents
Colored esmolol concentrate Download PDFInfo
- Publication number
- CA2686488A1 CA2686488A1 CA002686488A CA2686488A CA2686488A1 CA 2686488 A1 CA2686488 A1 CA 2686488A1 CA 002686488 A CA002686488 A CA 002686488A CA 2686488 A CA2686488 A CA 2686488A CA 2686488 A1 CA2686488 A1 CA 2686488A1
- Authority
- CA
- Canada
- Prior art keywords
- esmolol
- formulation
- concentrated
- propylene glycol
- colored
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation. The concentrated esmolol formulation can include from about 25 to about 1000 mg/ml of esmolol hydrochloride, a buffering agent and a color additive. Any number of color additives may be included such as indocyanine green, phenopheylene, hemoglobin, cyanocobalamine, patent blue, and indigo carmine vitamin B2 and naturally occurring vitamins and minerals. Also, a medical product is provided that includes a colored concentrated esmolol housed in a container, and a package housing the container and instructions. Additionally a method of allowing easy identification of a concentrated esmolol formulation is provided. The method includes providing a colored concentrated esmolol formulation that has from about 25 to about 1000 mg/ml of esmolol and a color additive.
Description
COLORED ESMOLOL CONCENTRATE
BACKGROUND OF THE INVENTION
[0001] The present invention is directed to colored enhanced concentrated esmolol formulations including a color additive. More specifically, the invention is directed to a concentrated esmolol formulation having a non-toxic color additive preferably approved for parenteral administration, preferably approved for I.V. administration. The invention is directed to a concentrated esmolol formulation having a color sufficient to be easily distinguishable from a dilution of the concentrate of at least a ratio of about one part concentrate to four parts diluent (1:4).
[0002] Administration of the proper dosage of a medication is one area where errors can arise. Most medications are safe and effective at the proper dosage but can have adverse consequences at high dosages. In some cases, dosing errors can have life threatening consequences.
BACKGROUND OF THE INVENTION
[0001] The present invention is directed to colored enhanced concentrated esmolol formulations including a color additive. More specifically, the invention is directed to a concentrated esmolol formulation having a non-toxic color additive preferably approved for parenteral administration, preferably approved for I.V. administration. The invention is directed to a concentrated esmolol formulation having a color sufficient to be easily distinguishable from a dilution of the concentrate of at least a ratio of about one part concentrate to four parts diluent (1:4).
[0002] Administration of the proper dosage of a medication is one area where errors can arise. Most medications are safe and effective at the proper dosage but can have adverse consequences at high dosages. In some cases, dosing errors can have life threatening consequences.
[0003] Dosing errors can unfortunately occur with respect to liquid medications that are provided in various strengths. This is especially true where the concentrated form of the medication is visually indistinguishable from a diluted form such as with substantially clear and colorless liquids. Liquid medications can come as ready-to-use formulations and in concentrated formulations, which require dilution prior to administration.
Usually the only means of differentiating between concentrated and diluted formulations is by the labeling of the container housing the medication. As an added precaution, the container itself or the closure may be given distinct attributes such as coloring. However, errors still occur because often times the medication is transferred to a secondary container such as a syringe.
Usually the only means of differentiating between concentrated and diluted formulations is by the labeling of the container housing the medication. As an added precaution, the container itself or the closure may be given distinct attributes such as coloring. However, errors still occur because often times the medication is transferred to a secondary container such as a syringe.
[0004] In order to assist health care practitioners to identify potentially hazardous concentrated potassium chloride formulations, there have been attempts to include a color additive. One known color, potassium chloride concentrate, uses methylene blue to assist practitioners in identifying the concentrate over the diluted form.
Unfortunately, due to the shortcomings of this colored concentrated potassium chloride formulation, coloring concentrated medical formulations have not been adopted with all medications in which the concentrated form can be potentially hazardous if administered directly and where the concentrated fonn of the medication is substantially indistinguishable from the diluted form.
p G
Unfortunately, due to the shortcomings of this colored concentrated potassium chloride formulation, coloring concentrated medical formulations have not been adopted with all medications in which the concentrated form can be potentially hazardous if administered directly and where the concentrated fonn of the medication is substantially indistinguishable from the diluted form.
p G
[0005] There are many commonly used safe and effective liquid medications that in concentrated form could be potentially hazardous and in which the concentrate liquid is indistinguishable from a diluted form of the liquid. One widely used liquid medication that can be provided both in concentrated form and a diluted ready-to-use form is methyl-3-[4-(2-hydroxy-3-isopropylamino) propoxy]phenylpropionate hydrochloride (esmolol hydrochloride).
[0006] Esmolol (and its pharmaceutically acceptable salts, e.g., hydrochloride salt) and related compounds have 0-adrenergic blocking activity. 0-blockers are therapeutically effective agents for the treatment and prophylaxis of cardiac disorders when administered in the appropriate dosage. However, high doses can cause dangerously low cardiac output.
Esmolol, which is a short-acting 0-blocker, is often times used in acute care settings to control the heart rate of a patient. Ready-to-use isotonic and concentrated formulations of esmolol hydrochloride and related compounds are disclosed in U.S. Patent Nos.
5,017,609, 6,310,094, and 6,528,540, incorporated herein by reference. Methods for making esmolol and related compounds and methods for treatment or prophylaxis of cardiac disorders using such compounds are disclosed in U.S. Patent 4,387,103 and 4.593,119, incorporated herein by reference.
Esmolol, which is a short-acting 0-blocker, is often times used in acute care settings to control the heart rate of a patient. Ready-to-use isotonic and concentrated formulations of esmolol hydrochloride and related compounds are disclosed in U.S. Patent Nos.
5,017,609, 6,310,094, and 6,528,540, incorporated herein by reference. Methods for making esmolol and related compounds and methods for treatment or prophylaxis of cardiac disorders using such compounds are disclosed in U.S. Patent 4,387,103 and 4.593,119, incorporated herein by reference.
[0007] Since esmolol formulations are substantially clear and colorless, the concentrated formulation is visually indistinguishable from a diluted formulation. Since esmolol hydrochloride can be provided as either a concentrate or in ready-to-use strength, it is desirable to have some means of identifying the concentrate once it has been removed from its primary container.
[0008] It would be desirable to provide a concentrated esmolol formulation that is readily distinguishable from a dilution of the colored concentrate.
SUMMARY OF THE INVENTION
[0009I In one aspect of the present invention, a colored concentrated esmolol formulation is provided. The colored concentrated esmolol formulation comprises from about 25 to about 1000 mg/ml of esmolol (or pharmaceutically acceptable salts thereof), from about 0.005 to about 2 M of a buffering agent, pH adjusted to between about 3.5 and about 7.0, and a color additive.
[00103 In another aspect of the present invention a medical product is provided. The medical product comprises a concentrated esmolol formulation including from about 25 to about 1000 mg/ml of esmolol (or a pharmaceutically acceptable salt thereof) and a color additive, instructions, and a package housing the colored concentrated esmolol formulation and instructions.
(00111 In yet another aspect of the present invention a method of distinguishing a concentrated esmolol formulation is provided. The method comprises the steps of providing a colored concentrated esmolol formulation including from about 25 to about 1000 mg/ml of esmolol (or a pharmaceutically acceptable salt thereof) and a color additive.
DETAILED DESCRIPTION OF THE INVENTION
[00121 In one embodiment of the present invention, a concentrated esmolol formulation is provided that is colored to permit identification of the concentrate, to be distinguishable from a dilution of the colored concentrate and to be distinguishable from other ready-to-use esmolol formulations. The colored concentrate is suitable for parental administration once diluted to the proper concentration.
(00131 The colored esmolol concentrate includes esmolol, or pharmaceutically acceptable salts thereof, e.g., hydrochloride, and a coloring agent in an aqueous solution. As used herein, "esmolol" refers to esmolol free base and pharmaceutically acceptable salts. The solution is preferably packaged in a suitable container and terminally sterilized by autoclaving. Alternatively, the colored esmolol concentrate can be prepared by asceptic fill procedures. The concentration of esmolol hydrochloride in the colored esmolol concentrate can be from about 25 to about 1000 mg/ml. Preferably, the esmolol concentration in the concentrate formulation ranges from about 50 to 500 mg/ml, more preferably from about 100 to 300 mg/n-A, and most preferably of about 250 mg/ml.
[00141 The colored concentrate may also include a pharmaceutically acceptable buffer to maintain the pH in a range of from about 3.5 to about 7Ø Preferably, the pH
is maintained between about 4.5 and about 5.5, more preferably between 4.9 and 5.1.
Degradation of esmolol occurs most rapidly when the pH is outside the range of 4.0 to 6.0 and is most stable around a pH of about 5Ø
[ 00151 Suitable buffers are those buffers that provide sufficient buffering capacity at the desired pH range and are pharmaceutically acceptable for injection into a patient. Examples of buffers useful in the present invention include, but are not limited to, acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine and conjugate acids thereof. The concentration of the buffer can be from about 0.005 molar (M) to about 2 M. In a preferred embodiment the buffering agent comprises a combination of sodium acetate and glacial acetic acid. A preferred combination of buffers can include sodium acetate at from about 0.005 to about 0.3 M and glacial acetic acid at from about 0.05 to about 0.3 M.
(00161 To improve the stability of the colored concentrate, one or more alcohols can be included. The one or more alcohols may be included at a concentration of from about I to about 60% by volume, depending on the alcohol or mixture of alcohols. A
preferred alcohol is ethanol, preferably included at a concentration of from about 5 to about 60% by volume, more preferably from about 10 to about 45% by volume and more preferably from about 20 to about 30% by volume. Another preferred alcohol is benzyl alcohol preferably included at a concentration of from about 1 to about 20% by volume.
[0017] For enhancing the stability of esmolol the colored esmolol concentrate can also contain a physiologically acceptable liquid polyhydric compound, preferably at a concentration of from about 5 to about 60% by volume, more preferably from about 10 to about 45% by volume and even more preferably from about 20 to about 30% by volume.
Physiologically acceptable liquid polyhydric compounds include, but are not limited to, alkyls of from I to about 10 carbon atoms having two or more adjacent hydroxyl groups such as ethylene glycol, propylene glycol, glycerol and the like;
polyethyleneglycols having a molecular weight of from about 200 to about 600 daltons; and glycerin.
Preferred liquid polyhydric compounds include alkyls of from 1 to about 10 carbon atoms having two or more adjacent hydroxyl groups, and polyethyleneglycols having a molecular weight of from about 200 to about 600 daltons. A preferred liquid polyhydric compound is propylene glycol. In a preferred embodiment liquid polyhydric compounds, in conjunction with ethanol are useful in stabilizing the concentrated esmolol solutions. A preferred combination includes ethanol and propylene glycol. In a preferred composition, the volume ratio of ethanol to the propylene glycol can be about 1:1. hi another preferred embodiment the concentration of ethanol is from about 20 to about 30% by volume, preferably about 26.5% by volume and the concentration of propylene glycol is from about 20 to about 30% by volume preferably about 25% by volume.
[00183 The colored concentrate includes one or more non-toxic or relatively non-toxic color additives. The color additives or agents used in the present invention are preferably approved for parenteral administration including intravenous administration.
Color agents include, but are not limited to, cyanocobalamin, indigo carmine, patent blue, indocyanine green, phenopheylene, and hemoglobin. The United States Food and Drug Administration has published and has listed at its website, www.cfsan.fda.gov/-dms/opa-col2.html or successor website, incorporated herein by reference, a series of colorants that have been used in foods, drugs and medical devices. It should be noted that not all of these color additives have been approved for parenteral use in all countries. A preferred set of colorants that maybe useful in the present invention include the vitamin-based agents, including, but not limited to, Vitamin B 12 (cyanocobalamin - pink in color). Vitamin B2 (riboflavin - orange in color). Other preferred colorants can include naturally occurring mineral based colorants.
The colorants listed and including those listed at the FDA website may be useful in the present invention so long as the colorants provide sufficient differentiating color, versus a clear solution, and are pharmaceutically acceptable for parenteral administration to a subject.
[00191 The amount of color additive is highly dependent on the specific coloring agent selected. The coloring agent should be added in an amount sufficient to clearly distinguish the colored esmolol concentrate from a diluted formulation containing esmolol.
Esmolol solutions are substantially clear and colorless even with the addition of the buffering agent or alcohol such as ethanol and propylene glycol in the concentrations disclosed above. In addition, an amount of the coloring agent should be added such that a dilution of at least about 1:4 of the colored esmolol concentrate produces a diluted esmolol formulation that is preferably more similar in color to an uncolored esmolol concentrate, i.e.
substantially clear and colorless or the color of the diluent, than to the starting colored concentrate.
[00201 In one embodiment, cyanocobalamin is included as the coloring agent of the colored esmolol concentrate at a concentration of from about 0.002 to about 0.003 mg/ml, preferably 0.0024 mg/ml. At such a concentration, the otherwise clear colorless esmolol solution is given a light pink color. When diluted at a ratio of at least 1:4 with a diluent suitable for parenteral administration such as Ringer's solution or I.V., the resulting solution is at least substantially colorless or the color of the diluent.
[00211 In another embodiment, indigo carmine is included as the coloring agent of the colored esmolol concentrate at a concentration of from about 0.0005 to about 0.001 mg/ml, preferably 0.0008 mg/ml. At such a concentration, the otherwise clear colorless esmolol concentrated solution is given a light blue color. When diluted at a ratio of at least 1:4 with a diluent suitable for parenteral administration such as Ringer's solution or I.V., the resulting solution is almost colorless or the color of the diluent.
[00223 In another embodiment, patent blue is included as the coloring agent of the colored esmolol concentrate at a concentration of from about 0.0001 to about 0.0003 mg/ml, preferably 0.0002 mg/ml. At such a concentration, the otherwise clear colorless esmolol concentrated solution is given a light blue color. When diluted at a ratio of at least 1:4 with a diluent suitable for parenteral administration such as Ringer's solution or I.V., the resulting solution is at least substantially colorless or the color of the diluent.
[0023] The colored esmolol concentrate can be diluted by isotonic solutions such as Ringers' or other diluents used in the art, or with water for injection to allow parenteral administration to a patient. For example, the diluted composition may be administered in the form of a bolus injection or intravenous infusion. Suitable routes for parenteral administration include intravenous, subcutaneous, intradermal, intramuscular, intraarticular and intrathecal. The diluted concentrate is preferably administered by intravenous infusion.
[00241 Suitable containers for housing the colored esmolol concentrate are known in the art. They include via], syringe, bag, bottle and ampul presentations and should be transparent or have a transparent portion to permit visually identification of the color.
Containers may be fabricated of polymeric materials or from glass. Preferred polymeric containers are free of polyvinychlorine (PVC). Preferably the container has excellent barrier properties. A
preferred container retains a moisture barrier such as glass containers or polymeric containers including barrier layers or secondary packaging. An aluminum overpouch is a preferred moisture barrier for use as secondary packaging for polymeric containers lacking a moisture barrier of their own.
[00257 Preferred containers should be able to withstand terminal sterilization such as autoclaving. Alternatively, the colored concentrate can be aseptically prepared or terminally sterilized via autoclaving separately and then placed in sterile containers using aseptic procedure. Typical autoclave cycles used in the pharmaceutical industry to achieve terminal sterilization of the final product are 121 C for 15 minutes. The colored esmolol concentrate of the present invention can be autoclaved at a temperature ranging from 115 to 130 C. for a period of time ranging from 5 to 40 minutes with acceptable stability.
Autoclaving is preferably carried out in the temperature range of 119 to 122 C for a period of time ranging from 10 to 36 minutes.
[00267 In one embodiment the colored concentrate is housed in a clear glass or polymer based syringe and terminally sterilized. These pre-filled syringes can be provided in various volumes to permit quick and easy preparation of either small volume or large volume parenteral dosage by dispensing the contents of the pre-filled syringes into standard pre-filled intravenous fluid bags. This would eliminate the risk of miscalculating the proper dilution. In another embodiment, the pre-filled syringe houses a colored esmolol concentrate having an esmolol concentration of about 25 to 1000 mg/ml.
[0027] In another embodiment of the present invention, a medical product includes a container housing a colored esmolol concentrate and instructions kept together in a single package. The container is clear and colorless or at least includes a portion that is clear and colorless. The instructions can inform the practitioner that a color additive has been added to indicate a concentrated formulation. The instructions can also provide either a description or a representation of the color of the undiluted colored esmolol concentrate or the colored concentrate after the recommended dilution or dilutions.
[0028] In yet another embodiment of the present invention, a method of allowing identification of a concentrated esmolol formulation is provided. The method can include the step of providing a colored concentrated esmolol formulation. The colored concentrated esmolol can include from about 25 to about 1000 mg/ml of esmolol and a color additive.
[0029] The following examples further illustrate the invention but, should not be construed as in any way limiting its scope.
Example 1 [0030] The following describes the preparation of a colored esmolol concentrate containing 250 mg/mL of esmolol HCl and a colorant after compounding, packaging and autoclave sterilization. The concentration of each ingredient of the composition is provided in Table 1 as follows:
Table 1 Ingredient Concentration Esmolol HC1 250 m mL
Sodium Acetate Trihydrate 17m mL
Glacial Acetic Acid 0.00715mUmI.
Alcohol, USP 0.265 mIJmL
Propylene Glycol,USP 0.25 mUniL
Cyanocobalamine 0.0024 mg/mL
Water for Injection, USP QS
[0031] The equipment and glassware for compounding, filtering, and filling are properly washed and depyrogenated. The filter assembly, filling tube assembly, and other parts and equipment are sterilized.
[0032] Eighty percent (80%) of the final volume of cool water for injection is collected in a compounding tank. Glacial acetic acid and sodium acetate are then added to the tank.
Esmolol Hydrochloride is weighed and added to the tank. Propylene glycol and ethanol are weighed and added to the tank. Required quantity of the colorant is weighed and added to the tank. The solution is stirred until all excipients are dissolved. The solution is then adjusted to pH 5.0 with 1.ON sodium hydroxide or hydrochloric acid. The solution is brought to final volume with water for injection and mixed. The colored esmolol concentrate is transferred to a container and autoclaved to provide an esmolol hydrochloride solution having a concentration of about 250 mg/nil.
[0033] The color is light pink and after 1:4 dilution of with water. The resulting 50 mg/ml esmolol solution is clear and colorless and has a concentration of about 0.00048 mg/ml cyanocobalamine.
SUMMARY OF THE INVENTION
[0009I In one aspect of the present invention, a colored concentrated esmolol formulation is provided. The colored concentrated esmolol formulation comprises from about 25 to about 1000 mg/ml of esmolol (or pharmaceutically acceptable salts thereof), from about 0.005 to about 2 M of a buffering agent, pH adjusted to between about 3.5 and about 7.0, and a color additive.
[00103 In another aspect of the present invention a medical product is provided. The medical product comprises a concentrated esmolol formulation including from about 25 to about 1000 mg/ml of esmolol (or a pharmaceutically acceptable salt thereof) and a color additive, instructions, and a package housing the colored concentrated esmolol formulation and instructions.
(00111 In yet another aspect of the present invention a method of distinguishing a concentrated esmolol formulation is provided. The method comprises the steps of providing a colored concentrated esmolol formulation including from about 25 to about 1000 mg/ml of esmolol (or a pharmaceutically acceptable salt thereof) and a color additive.
DETAILED DESCRIPTION OF THE INVENTION
[00121 In one embodiment of the present invention, a concentrated esmolol formulation is provided that is colored to permit identification of the concentrate, to be distinguishable from a dilution of the colored concentrate and to be distinguishable from other ready-to-use esmolol formulations. The colored concentrate is suitable for parental administration once diluted to the proper concentration.
(00131 The colored esmolol concentrate includes esmolol, or pharmaceutically acceptable salts thereof, e.g., hydrochloride, and a coloring agent in an aqueous solution. As used herein, "esmolol" refers to esmolol free base and pharmaceutically acceptable salts. The solution is preferably packaged in a suitable container and terminally sterilized by autoclaving. Alternatively, the colored esmolol concentrate can be prepared by asceptic fill procedures. The concentration of esmolol hydrochloride in the colored esmolol concentrate can be from about 25 to about 1000 mg/ml. Preferably, the esmolol concentration in the concentrate formulation ranges from about 50 to 500 mg/ml, more preferably from about 100 to 300 mg/n-A, and most preferably of about 250 mg/ml.
[00141 The colored concentrate may also include a pharmaceutically acceptable buffer to maintain the pH in a range of from about 3.5 to about 7Ø Preferably, the pH
is maintained between about 4.5 and about 5.5, more preferably between 4.9 and 5.1.
Degradation of esmolol occurs most rapidly when the pH is outside the range of 4.0 to 6.0 and is most stable around a pH of about 5Ø
[ 00151 Suitable buffers are those buffers that provide sufficient buffering capacity at the desired pH range and are pharmaceutically acceptable for injection into a patient. Examples of buffers useful in the present invention include, but are not limited to, acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine and conjugate acids thereof. The concentration of the buffer can be from about 0.005 molar (M) to about 2 M. In a preferred embodiment the buffering agent comprises a combination of sodium acetate and glacial acetic acid. A preferred combination of buffers can include sodium acetate at from about 0.005 to about 0.3 M and glacial acetic acid at from about 0.05 to about 0.3 M.
(00161 To improve the stability of the colored concentrate, one or more alcohols can be included. The one or more alcohols may be included at a concentration of from about I to about 60% by volume, depending on the alcohol or mixture of alcohols. A
preferred alcohol is ethanol, preferably included at a concentration of from about 5 to about 60% by volume, more preferably from about 10 to about 45% by volume and more preferably from about 20 to about 30% by volume. Another preferred alcohol is benzyl alcohol preferably included at a concentration of from about 1 to about 20% by volume.
[0017] For enhancing the stability of esmolol the colored esmolol concentrate can also contain a physiologically acceptable liquid polyhydric compound, preferably at a concentration of from about 5 to about 60% by volume, more preferably from about 10 to about 45% by volume and even more preferably from about 20 to about 30% by volume.
Physiologically acceptable liquid polyhydric compounds include, but are not limited to, alkyls of from I to about 10 carbon atoms having two or more adjacent hydroxyl groups such as ethylene glycol, propylene glycol, glycerol and the like;
polyethyleneglycols having a molecular weight of from about 200 to about 600 daltons; and glycerin.
Preferred liquid polyhydric compounds include alkyls of from 1 to about 10 carbon atoms having two or more adjacent hydroxyl groups, and polyethyleneglycols having a molecular weight of from about 200 to about 600 daltons. A preferred liquid polyhydric compound is propylene glycol. In a preferred embodiment liquid polyhydric compounds, in conjunction with ethanol are useful in stabilizing the concentrated esmolol solutions. A preferred combination includes ethanol and propylene glycol. In a preferred composition, the volume ratio of ethanol to the propylene glycol can be about 1:1. hi another preferred embodiment the concentration of ethanol is from about 20 to about 30% by volume, preferably about 26.5% by volume and the concentration of propylene glycol is from about 20 to about 30% by volume preferably about 25% by volume.
[00183 The colored concentrate includes one or more non-toxic or relatively non-toxic color additives. The color additives or agents used in the present invention are preferably approved for parenteral administration including intravenous administration.
Color agents include, but are not limited to, cyanocobalamin, indigo carmine, patent blue, indocyanine green, phenopheylene, and hemoglobin. The United States Food and Drug Administration has published and has listed at its website, www.cfsan.fda.gov/-dms/opa-col2.html or successor website, incorporated herein by reference, a series of colorants that have been used in foods, drugs and medical devices. It should be noted that not all of these color additives have been approved for parenteral use in all countries. A preferred set of colorants that maybe useful in the present invention include the vitamin-based agents, including, but not limited to, Vitamin B 12 (cyanocobalamin - pink in color). Vitamin B2 (riboflavin - orange in color). Other preferred colorants can include naturally occurring mineral based colorants.
The colorants listed and including those listed at the FDA website may be useful in the present invention so long as the colorants provide sufficient differentiating color, versus a clear solution, and are pharmaceutically acceptable for parenteral administration to a subject.
[00191 The amount of color additive is highly dependent on the specific coloring agent selected. The coloring agent should be added in an amount sufficient to clearly distinguish the colored esmolol concentrate from a diluted formulation containing esmolol.
Esmolol solutions are substantially clear and colorless even with the addition of the buffering agent or alcohol such as ethanol and propylene glycol in the concentrations disclosed above. In addition, an amount of the coloring agent should be added such that a dilution of at least about 1:4 of the colored esmolol concentrate produces a diluted esmolol formulation that is preferably more similar in color to an uncolored esmolol concentrate, i.e.
substantially clear and colorless or the color of the diluent, than to the starting colored concentrate.
[00201 In one embodiment, cyanocobalamin is included as the coloring agent of the colored esmolol concentrate at a concentration of from about 0.002 to about 0.003 mg/ml, preferably 0.0024 mg/ml. At such a concentration, the otherwise clear colorless esmolol solution is given a light pink color. When diluted at a ratio of at least 1:4 with a diluent suitable for parenteral administration such as Ringer's solution or I.V., the resulting solution is at least substantially colorless or the color of the diluent.
[00211 In another embodiment, indigo carmine is included as the coloring agent of the colored esmolol concentrate at a concentration of from about 0.0005 to about 0.001 mg/ml, preferably 0.0008 mg/ml. At such a concentration, the otherwise clear colorless esmolol concentrated solution is given a light blue color. When diluted at a ratio of at least 1:4 with a diluent suitable for parenteral administration such as Ringer's solution or I.V., the resulting solution is almost colorless or the color of the diluent.
[00223 In another embodiment, patent blue is included as the coloring agent of the colored esmolol concentrate at a concentration of from about 0.0001 to about 0.0003 mg/ml, preferably 0.0002 mg/ml. At such a concentration, the otherwise clear colorless esmolol concentrated solution is given a light blue color. When diluted at a ratio of at least 1:4 with a diluent suitable for parenteral administration such as Ringer's solution or I.V., the resulting solution is at least substantially colorless or the color of the diluent.
[0023] The colored esmolol concentrate can be diluted by isotonic solutions such as Ringers' or other diluents used in the art, or with water for injection to allow parenteral administration to a patient. For example, the diluted composition may be administered in the form of a bolus injection or intravenous infusion. Suitable routes for parenteral administration include intravenous, subcutaneous, intradermal, intramuscular, intraarticular and intrathecal. The diluted concentrate is preferably administered by intravenous infusion.
[00241 Suitable containers for housing the colored esmolol concentrate are known in the art. They include via], syringe, bag, bottle and ampul presentations and should be transparent or have a transparent portion to permit visually identification of the color.
Containers may be fabricated of polymeric materials or from glass. Preferred polymeric containers are free of polyvinychlorine (PVC). Preferably the container has excellent barrier properties. A
preferred container retains a moisture barrier such as glass containers or polymeric containers including barrier layers or secondary packaging. An aluminum overpouch is a preferred moisture barrier for use as secondary packaging for polymeric containers lacking a moisture barrier of their own.
[00257 Preferred containers should be able to withstand terminal sterilization such as autoclaving. Alternatively, the colored concentrate can be aseptically prepared or terminally sterilized via autoclaving separately and then placed in sterile containers using aseptic procedure. Typical autoclave cycles used in the pharmaceutical industry to achieve terminal sterilization of the final product are 121 C for 15 minutes. The colored esmolol concentrate of the present invention can be autoclaved at a temperature ranging from 115 to 130 C. for a period of time ranging from 5 to 40 minutes with acceptable stability.
Autoclaving is preferably carried out in the temperature range of 119 to 122 C for a period of time ranging from 10 to 36 minutes.
[00267 In one embodiment the colored concentrate is housed in a clear glass or polymer based syringe and terminally sterilized. These pre-filled syringes can be provided in various volumes to permit quick and easy preparation of either small volume or large volume parenteral dosage by dispensing the contents of the pre-filled syringes into standard pre-filled intravenous fluid bags. This would eliminate the risk of miscalculating the proper dilution. In another embodiment, the pre-filled syringe houses a colored esmolol concentrate having an esmolol concentration of about 25 to 1000 mg/ml.
[0027] In another embodiment of the present invention, a medical product includes a container housing a colored esmolol concentrate and instructions kept together in a single package. The container is clear and colorless or at least includes a portion that is clear and colorless. The instructions can inform the practitioner that a color additive has been added to indicate a concentrated formulation. The instructions can also provide either a description or a representation of the color of the undiluted colored esmolol concentrate or the colored concentrate after the recommended dilution or dilutions.
[0028] In yet another embodiment of the present invention, a method of allowing identification of a concentrated esmolol formulation is provided. The method can include the step of providing a colored concentrated esmolol formulation. The colored concentrated esmolol can include from about 25 to about 1000 mg/ml of esmolol and a color additive.
[0029] The following examples further illustrate the invention but, should not be construed as in any way limiting its scope.
Example 1 [0030] The following describes the preparation of a colored esmolol concentrate containing 250 mg/mL of esmolol HCl and a colorant after compounding, packaging and autoclave sterilization. The concentration of each ingredient of the composition is provided in Table 1 as follows:
Table 1 Ingredient Concentration Esmolol HC1 250 m mL
Sodium Acetate Trihydrate 17m mL
Glacial Acetic Acid 0.00715mUmI.
Alcohol, USP 0.265 mIJmL
Propylene Glycol,USP 0.25 mUniL
Cyanocobalamine 0.0024 mg/mL
Water for Injection, USP QS
[0031] The equipment and glassware for compounding, filtering, and filling are properly washed and depyrogenated. The filter assembly, filling tube assembly, and other parts and equipment are sterilized.
[0032] Eighty percent (80%) of the final volume of cool water for injection is collected in a compounding tank. Glacial acetic acid and sodium acetate are then added to the tank.
Esmolol Hydrochloride is weighed and added to the tank. Propylene glycol and ethanol are weighed and added to the tank. Required quantity of the colorant is weighed and added to the tank. The solution is stirred until all excipients are dissolved. The solution is then adjusted to pH 5.0 with 1.ON sodium hydroxide or hydrochloric acid. The solution is brought to final volume with water for injection and mixed. The colored esmolol concentrate is transferred to a container and autoclaved to provide an esmolol hydrochloride solution having a concentration of about 250 mg/nil.
[0033] The color is light pink and after 1:4 dilution of with water. The resulting 50 mg/ml esmolol solution is clear and colorless and has a concentration of about 0.00048 mg/ml cyanocobalamine.
Example 2 [0034] The following describes the preparation of a colored esmolol concentrate containing 250 mg/mL of esmolol HCI and a colorant after compounding, packaging and autoclave sterilization. The concentration of each ingredient of the composition is provided in Table 2 as follows:
Table 2 Ingredient Concentration Esmolol HCL 250 mg/mL
Sodium Acetate Trihydrate 17m mL
Glacial Acetic Acid 0.00715mIJrnL
Alcohol, USP 0.265 mLJmL
Propylene Glycol,USP 0.25 mIJmL
Patent Blue 0.0002 m mL
Water for Injection, USP Qs [0035] The formulation of Table 2 was made similarly to the formulation of Example 1, with the exception of the different colorant and concentration.
[0036] The color is light blue and after 1:4 dilution of with water. The resulting 50 mg/ml esmolol solution is clear and colorless and has a concentration of about 0.000004 mg/ml patent blue.
Example 3 [00373 The following describes the preparation of a colored esmolol concentrate containing 250 mg/mL of esmolol HCI and a colorant after compounding, packaging and autoclave sterilization. The concentration of each ingredient of the composition is provided in Table 3 as follows:
Table 3 Ingredient Concentration Esmolol HCL 250 mg/mL
Sodium Acetate Trihydrate 17m mL
Glacial Acetic Acid 0.00715mIJmL
Alcohol, USP 0.265 mL/mL
Propylene Glycol,USP 0.25 mL/mL
Indi o Carmine 0.0008 m mL
Water for In'ection, USP Qs [0038] The formulation of Table 3 was made similarly to the formulation of Example 1, with the exception of the different colorant and concentration.
Example 4 [00393 The following describes the preparation of an esmolol concentrate containing from 25-1000 mg/mL of Esmolol HCL and benzyl alcohol. The concentration of each ingredient of the composition is as follows:
Table 4 Ingredient Concentration Esmolol HCL 25-1000 mg/mL
Sodium Acetate Trihydrate 17m mL
Glacial Acetic Acid 0.00715mL/mL
Benzyl Alcohol, USP 1-10%
Water for Injection, USP Qs [0040] The equipment and glassware for compounding, filtering, and filling are properly washed and depyrogenated. The filter assembly, filling tube assembly, and other parts and equipment are sterilized.
[00411 Eighty percent (80%) of the final volume of cool water for injection is collected in a compounding tank. Glacial acetic acid and sodium acetate are then added to the tank.
Esmolol hydrochloride is weighed and added to the tank. Required quantity of the benzyl alcohol is weighed and added to the tank. The solution is stirred until all excipients are dissolved. The solution is then adjusted to pH 5.0 with 1.ON sodium hydroxide or hydrochloric acid. The solution is brought to final volume with water for injection and mixed.
[00421 Although the present invention has been described by reference to certain preferred embodiments, it should be understood that the preferred embodiments are merely illustrative of the principles of the present invention. Therefore, modifications and/or changes may be made by those skilled in the art without departing from the true spirit and scope of the invention as defmed by the appended claims.
Table 2 Ingredient Concentration Esmolol HCL 250 mg/mL
Sodium Acetate Trihydrate 17m mL
Glacial Acetic Acid 0.00715mIJrnL
Alcohol, USP 0.265 mLJmL
Propylene Glycol,USP 0.25 mIJmL
Patent Blue 0.0002 m mL
Water for Injection, USP Qs [0035] The formulation of Table 2 was made similarly to the formulation of Example 1, with the exception of the different colorant and concentration.
[0036] The color is light blue and after 1:4 dilution of with water. The resulting 50 mg/ml esmolol solution is clear and colorless and has a concentration of about 0.000004 mg/ml patent blue.
Example 3 [00373 The following describes the preparation of a colored esmolol concentrate containing 250 mg/mL of esmolol HCI and a colorant after compounding, packaging and autoclave sterilization. The concentration of each ingredient of the composition is provided in Table 3 as follows:
Table 3 Ingredient Concentration Esmolol HCL 250 mg/mL
Sodium Acetate Trihydrate 17m mL
Glacial Acetic Acid 0.00715mIJmL
Alcohol, USP 0.265 mL/mL
Propylene Glycol,USP 0.25 mL/mL
Indi o Carmine 0.0008 m mL
Water for In'ection, USP Qs [0038] The formulation of Table 3 was made similarly to the formulation of Example 1, with the exception of the different colorant and concentration.
Example 4 [00393 The following describes the preparation of an esmolol concentrate containing from 25-1000 mg/mL of Esmolol HCL and benzyl alcohol. The concentration of each ingredient of the composition is as follows:
Table 4 Ingredient Concentration Esmolol HCL 25-1000 mg/mL
Sodium Acetate Trihydrate 17m mL
Glacial Acetic Acid 0.00715mL/mL
Benzyl Alcohol, USP 1-10%
Water for Injection, USP Qs [0040] The equipment and glassware for compounding, filtering, and filling are properly washed and depyrogenated. The filter assembly, filling tube assembly, and other parts and equipment are sterilized.
[00411 Eighty percent (80%) of the final volume of cool water for injection is collected in a compounding tank. Glacial acetic acid and sodium acetate are then added to the tank.
Esmolol hydrochloride is weighed and added to the tank. Required quantity of the benzyl alcohol is weighed and added to the tank. The solution is stirred until all excipients are dissolved. The solution is then adjusted to pH 5.0 with 1.ON sodium hydroxide or hydrochloric acid. The solution is brought to final volume with water for injection and mixed.
[00421 Although the present invention has been described by reference to certain preferred embodiments, it should be understood that the preferred embodiments are merely illustrative of the principles of the present invention. Therefore, modifications and/or changes may be made by those skilled in the art without departing from the true spirit and scope of the invention as defmed by the appended claims.
Claims (19)
1. A colored concentrated esmolol formulation comprising:
a) from about 25 to about 1000 mg/ml of esmolol;
b) from about 0.005 to about 2 M of a buffering agent; and c) a color additive selected from the group consisting of indocyanine green, phenopheylene, hemoglobin, cyanocobalamin, patent blue, indigo carmine, vitamin B2 and naturally occurring vitamins and minerals;
wherein the formulation has a pH of from about 3.5 to about 7Ø
a) from about 25 to about 1000 mg/ml of esmolol;
b) from about 0.005 to about 2 M of a buffering agent; and c) a color additive selected from the group consisting of indocyanine green, phenopheylene, hemoglobin, cyanocobalamin, patent blue, indigo carmine, vitamin B2 and naturally occurring vitamins and minerals;
wherein the formulation has a pH of from about 3.5 to about 7Ø
2. The formulation of claim 1, wherein the buffering agent comprises at least one of acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine and conjugate acids thereof.
3. The formulation of claim 2, wherein the buffering agent comprises sodium acetate and acetic acid.
4. The formulation of claim 3 further comprising from about 1 to about 60% by volume ethanol and from about 5 to about 60% by volume propylene glycol.
5. The formulation of claim 4 comprising about 26.5% by volume ethanol and 25%
by volume propylene glycol.
by volume propylene glycol.
6. The formulation of claim 1, wherein the coloring agent is cyanocobalamine.
7. The formulation of claim 1 wherein the coloring agent is selected from the group consisting of from about 0.002 to about 0.003 mg/ml of cyanocobalamine, from about 0.0005 to about 0.001 mg/ml of indigo carmine and from about 0.0001 to about 0.0003 mg/ml of patent blue.
8. The formulation of claim 1 comprising:
a) about 250 mg/ml esmolol HCl;
b) about 17mg/ml sodium acetate trihydrate;
c) about 0.00715 ml/ml glacial acetic acid;
d) about 0.265 ml/ml ethanol;
e) about 0.25 ml/ml propylene glycol; and f) about 0.0024 mg/ml cyanocobalamine.
a) about 250 mg/ml esmolol HCl;
b) about 17mg/ml sodium acetate trihydrate;
c) about 0.00715 ml/ml glacial acetic acid;
d) about 0.265 ml/ml ethanol;
e) about 0.25 ml/ml propylene glycol; and f) about 0.0024 mg/ml cyanocobalamine.
9. The formulation of claim 1 comprising:
a) about 250 mg/ml esmolol HCl;
b) about 17mg/ml sodium acetate trihydrate;
c) about 0.00715 ml/ml glacial acetic acid;
d) about 0.265 ml/ml ethanol;
e) about 0.25 ml/ml propylene glycol; and f) about 0.0002 mg/ml patent blue.
a) about 250 mg/ml esmolol HCl;
b) about 17mg/ml sodium acetate trihydrate;
c) about 0.00715 ml/ml glacial acetic acid;
d) about 0.265 ml/ml ethanol;
e) about 0.25 ml/ml propylene glycol; and f) about 0.0002 mg/ml patent blue.
10. The formulation of claim 1 comprising:
a) about 250 mg/ml esmolol HCl;
b) about 17mg/ml sodium acetate trihydrate;
c) about 0.00715 ml/ml glacial acetic acid;
d) about 0.265 ml/ml ethanol;
e) about 0.25 ml/ml propylene glycol; and f) about 0.0008 mg/ml indigo carmine.
a) about 250 mg/ml esmolol HCl;
b) about 17mg/ml sodium acetate trihydrate;
c) about 0.00715 ml/ml glacial acetic acid;
d) about 0.265 ml/ml ethanol;
e) about 0.25 ml/ml propylene glycol; and f) about 0.0008 mg/ml indigo carmine.
11. A medical product comprising:
a) a concentrated esmolol formulation comprising from about 25 to about 1000 mg/ml of esmolol hydrochloride, about 0.005 to about 2 M of a buffering agent and a color additive selected from the group consisting of indocyanine green, phenopheylene, hemoglobin, cyanocobalamin, patent blue, indigo carmine, vitamin B2 and naturally occurring vitamins and minerals housed in a container;
b) instructions; and c) a package housing the container and instructions.
a) a concentrated esmolol formulation comprising from about 25 to about 1000 mg/ml of esmolol hydrochloride, about 0.005 to about 2 M of a buffering agent and a color additive selected from the group consisting of indocyanine green, phenopheylene, hemoglobin, cyanocobalamin, patent blue, indigo carmine, vitamin B2 and naturally occurring vitamins and minerals housed in a container;
b) instructions; and c) a package housing the container and instructions.
12. The medical product of claim 11, wherein the buffering agent comprises at least one of acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine and conjugate acids thereof.
13. The medical product of claim 12, wherein the buffering agent comprises sodium acetate and acetic acid.
14. The medical product of claim 13 further comprising from about 5 to about 60% by volume ethanol and from about 5 to about 60% by volume propylene glycol.
15. The medical product of claim 14 comprising about 26.5% by volume ethanol and 25%
by volume propylene glycol.
by volume propylene glycol.
16. The medical product of claim 11 wherein the color additive is selected from the group consisting of from about 0.002 to about 0.003 mg/ml of cyanocobalamine, from about 0.0005 to about 0.001 mg/ml of indigo carmine and from about 0.0001 to about 0.0003 mg/ml of patent blue.
17. The medical product of claim 11, wherein the formulation comprises:
a) about 250 mg/ml esmolol HCl;
b) about 17mg/ml sodium acetate trihydrate;
c) about 0.00715 ml/ml glacial acetic acid;
d) about 0.265 ml/ml ethanol;
e) about 0.25 ml/ml propylene glycol; and f) a color additive and amount selected from the group consisting of about 0.0008 mg/ml indigo carmine, about 0.0002 mg/nil patent blue, about 0.0024 mg/ml cyanocobalamine
a) about 250 mg/ml esmolol HCl;
b) about 17mg/ml sodium acetate trihydrate;
c) about 0.00715 ml/ml glacial acetic acid;
d) about 0.265 ml/ml ethanol;
e) about 0.25 ml/ml propylene glycol; and f) a color additive and amount selected from the group consisting of about 0.0008 mg/ml indigo carmine, about 0.0002 mg/nil patent blue, about 0.0024 mg/ml cyanocobalamine
18. The medical product of claim 11 wherein the instructions notify that a color additive has been added to the concentrated esmolol formulation.
19. A method of allowing easy identification of a concentrated esmolol formulation comprising the steps of:
a) providing a colored concentrated esmolol formulation including from about to about 1000 mg/ml of esmolol and a color additive selected from the group consisting of indocyanine green, phenopheylene, hemoglobin, cyanocobalamin, patent blue, indigo carmine, vitamin B2 and naturally occurring vitamins and minerals.
a) providing a colored concentrated esmolol formulation including from about to about 1000 mg/ml of esmolol and a color additive selected from the group consisting of indocyanine green, phenopheylene, hemoglobin, cyanocobalamin, patent blue, indigo carmine, vitamin B2 and naturally occurring vitamins and minerals.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/752,086 US8426467B2 (en) | 2007-05-22 | 2007-05-22 | Colored esmolol concentrate |
| US11/752,086 | 2007-05-22 | ||
| PCT/US2007/075069 WO2008143682A1 (en) | 2007-05-22 | 2007-08-02 | Colored esmolol concentrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2686488A1 true CA2686488A1 (en) | 2008-11-27 |
Family
ID=39232832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002686488A Abandoned CA2686488A1 (en) | 2007-05-22 | 2007-08-02 | Colored esmolol concentrate |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8426467B2 (en) |
| EP (1) | EP2162154B1 (en) |
| JP (1) | JP5825785B2 (en) |
| KR (1) | KR20100022991A (en) |
| CN (1) | CN101678111B (en) |
| AT (1) | ATE512673T1 (en) |
| AU (1) | AU2007353795B2 (en) |
| BR (1) | BRPI0721681A2 (en) |
| CA (1) | CA2686488A1 (en) |
| MX (1) | MX2009012620A (en) |
| WO (1) | WO2008143682A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6081241B2 (en) * | 2013-03-13 | 2017-02-15 | テルモ株式会社 | Remifentanil injection preparation containing colorant |
| US8835505B1 (en) * | 2013-03-15 | 2014-09-16 | Welgrace Research Group | Ready-to-use co-solvents pharmaceutical composition in modified flexible plastic container |
| WO2016038735A1 (en) * | 2014-09-12 | 2016-03-17 | テルモ株式会社 | Remifentanil injection containing coloring agent |
| US10265312B1 (en) * | 2018-02-01 | 2019-04-23 | Jason Ahee | Antibiotic solution and method of injection to prevent ophthalmic infections |
Family Cites Families (221)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2525071A (en) | 1945-11-30 | 1950-10-10 | Standard Oil Dev Co | Laminated sheet material and compositions |
| BE515475A (en) | 1951-11-13 | |||
| US2745785A (en) | 1952-10-29 | 1956-05-15 | American Home Prod | Therapeutic composition comprising tabular nu, nu'-dibenzylethylenediamine di-penicillin, and process for preparing same |
| US3685261A (en) | 1971-02-16 | 1972-08-22 | Environeering | Wet scrubber for contaminated gas |
| US4798846A (en) | 1974-03-28 | 1989-01-17 | Imperial Chemical Industries Plc | Pharmaceutical compositions |
| GB1472793A (en) | 1974-03-28 | 1977-05-04 | Ici Ltd | Pharmaceutical compositions |
| US4073943A (en) | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
| JPS597693B2 (en) | 1978-01-07 | 1984-02-20 | 株式会社ミドリ十字 | Antithrombin preparation and its manufacturing method |
| DE3013839A1 (en) | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | METHOD FOR PRODUCING AN ACTIVATED PHARMACEUTICAL COMPOSITION |
| US4387103A (en) | 1980-11-28 | 1983-06-07 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
| US4593119A (en) | 1980-11-28 | 1986-06-03 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
| US4725442A (en) | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
| US4622219A (en) | 1983-06-17 | 1986-11-11 | Haynes Duncan H | Method of inducing local anesthesia using microdroplets of a general anesthetic |
| US4606939A (en) | 1983-06-22 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation |
| US4608278A (en) | 1983-06-22 | 1986-08-26 | The Ohio State University Research Foundation | Small particule formation and encapsulation |
| EP0179808B1 (en) | 1984-04-09 | 1991-10-30 | The Du Pont Merck Pharmaceutical Company | Pharmaceutical composition suitable for treatment or prophylaxis of cardiac disorders |
| CA1282405C (en) | 1984-05-21 | 1991-04-02 | Michael R. Violante | Method for making uniformly sized particles from water-insoluble organic compounds |
| US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
| US4606940A (en) | 1984-12-21 | 1986-08-19 | The Ohio State University Research Foundation | Small particle formation and encapsulation |
| US5354563A (en) | 1985-07-15 | 1994-10-11 | Research Development Corp. Of Japan | Water dispersion containing ultrafine particles of organic compounds |
| US5023271A (en) | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
| US5171566A (en) | 1986-05-16 | 1992-12-15 | The Green Cross Corporation | Flurbiprofen derivative ophthalmic preparation |
| GB8618846D0 (en) | 1986-08-01 | 1986-09-10 | Smithkline Beckman Corp | Chemical process |
| CA1338736C (en) | 1986-12-05 | 1996-11-26 | Roger Baurain | Microcrystals containing an active ingredient with affinity for phospholipids and at least one phospholipid; process for preparing the same |
| US5174930A (en) | 1986-12-31 | 1992-12-29 | Centre National De La Recherche Scientifique (Cnrs) | Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions |
| FR2634397B2 (en) | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF DISPERSIBLE COLLOIDAL SYSTEMS OF A PROTEIN IN THE FORM OF NANOPARTICLES |
| FR2608988B1 (en) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES |
| FR2608942B1 (en) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOCAPSULES |
| IL86211A (en) | 1987-05-04 | 1992-03-29 | Ciba Geigy Ag | Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation |
| GB8901254D0 (en) | 1989-01-20 | 1989-03-15 | Allied Colloids Ltd | Particulate materials and their production |
| FR2631826B1 (en) | 1988-05-27 | 1992-06-19 | Centre Nat Rech Scient | PARTICULATE VECTOR USEFUL IN PARTICULAR FOR THE TRANSPORT OF BIOLOGICALLY ACTIVATED MOLECULES AND METHOD FOR THE PREPARATION THEREOF |
| IL90561A (en) | 1988-06-08 | 1993-08-18 | Fountain Pharm Inc | Method for making solvent dilution microcarriers |
| US5269979A (en) | 1988-06-08 | 1993-12-14 | Fountain Pharmaceuticals, Inc. | Method for making solvent dilution microcarriers |
| US4857552A (en) * | 1988-06-08 | 1989-08-15 | E. I. Du Pont De Nemours And Co. | Stable pharmaceutical composition |
| EP0349428B1 (en) | 1988-06-30 | 1993-01-20 | Centre National De La Recherche Scientifique (Cnrs) | Process for preparing colloidal dispersive protein systems in the shape of nanoparticles |
| US5707634A (en) | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| US5474989A (en) | 1988-11-11 | 1995-12-12 | Kurita Water Industries, Ltd. | Drug composition |
| IL92344A0 (en) | 1989-01-04 | 1990-07-26 | Gist Brocades Nv | Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules |
| CH677886A5 (en) | 1989-06-26 | 1991-07-15 | Hans Georg Prof Dr Weder | |
| FR2651680B1 (en) | 1989-09-14 | 1991-12-27 | Medgenix Group Sa | NOVEL PROCESS FOR THE PREPARATION OF LIPID MICROPARTICLES. |
| JP2602964B2 (en) | 1989-10-16 | 1997-04-23 | 裕 水島 | Prostaglandin analogs and their fat emulsions |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5078994A (en) | 1990-04-12 | 1992-01-07 | Eastman Kodak Company | Microgel drug delivery system |
| US5091187A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
| US5246707A (en) | 1990-04-26 | 1993-09-21 | Haynes Duncan H | Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes |
| EP0461930B1 (en) | 1990-06-15 | 1995-09-13 | Merck & Co. Inc. | A crystallization method to improve crystal structure and size |
| CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
| US5552160A (en) | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| AU642066B2 (en) | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5306519A (en) | 1991-05-23 | 1994-04-26 | Universal Foods Corporation | Syrup for confections and methods for using same |
| IT1247472B (en) | 1991-05-31 | 1994-12-17 | Fidia Spa | PROCESS FOR THE PREPARATION OF MICROSPHERES CONTAINING BIOLOGICALLY ACTIVE COMPONENTS. |
| US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| CH683149A5 (en) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Process for the preparation of microspheres of a biodegradable polymeric material. |
| US5250236A (en) | 1991-08-05 | 1993-10-05 | Gasco Maria R | Method for producing solid lipid microspheres having a narrow size distribution |
| CA2078388A1 (en) | 1991-10-02 | 1993-04-03 | Mridula Nair | Biocompatible emulsion particles |
| US6063910A (en) | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
| US5298483A (en) | 1992-03-30 | 1994-03-29 | Tropicana Products, Inc. | New matter of composition and method for using the same as plant bioregulators |
| US5389263A (en) | 1992-05-20 | 1995-02-14 | Phasex Corporation | Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX |
| DK0644755T3 (en) | 1992-06-10 | 1997-09-22 | Nanosystems Llc | Surface Modified NSAID Nanoparticles |
| JP3961029B2 (en) | 1992-06-24 | 2007-08-15 | 博 木戸 | Influenza virus infection inhibitor |
| SE9202128D0 (en) | 1992-07-09 | 1992-07-09 | Astra Ab | PRECIPITATION OF ONE OR MORE ACTIVE COMPOUNDS IN SITU |
| US5417956A (en) | 1992-08-18 | 1995-05-23 | Worcester Polytechnic Institute | Preparation of nanophase solid state materials |
| US5466646A (en) | 1992-08-18 | 1995-11-14 | Worcester Polytechnic Institute | Process for the preparation of solid state materials and said materials |
| AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
| US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
| US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
| US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
| US5340564A (en) | 1992-12-10 | 1994-08-23 | Sterling Winthrop Inc. | Formulations comprising olin 10-G to prevent particle aggregation and increase stability |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
| US5352459A (en) | 1992-12-16 | 1994-10-04 | Sterling Winthrop Inc. | Use of purified surface modifiers to prevent particle aggregation during sterilization |
| US5326552A (en) | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
| DE4305003A1 (en) | 1993-02-18 | 1994-08-25 | Knoll Ag | Process for the preparation of colloidal aqueous solutions of poorly soluble active substances |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5885486A (en) | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| FR2703927B1 (en) | 1993-04-13 | 1995-07-13 | Coletica | Use of a transacylation reaction between an esterified polysaccharide and a polyamine to form in an aqueous medium a membrane at least on the surface of gelled particles. |
| US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US6596260B1 (en) | 1993-08-27 | 2003-07-22 | Novartis Corporation | Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol |
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| EP0720605B1 (en) | 1993-09-24 | 2001-12-19 | University Of British Columbia | Aminocyclohexylesters and uses thereof |
| SE9303574D0 (en) | 1993-11-01 | 1993-11-01 | Kabi Pharmacia Ab | Composition for drug delivery and method of manufacturing thereof |
| ATE167980T1 (en) | 1993-11-15 | 1998-07-15 | Zeneca Ltd | MICRO CAPSULES CONTAINING SUSPENSIONS OF BIOLOGICALLY ACTIVE COMPOUNDS |
| US5468224A (en) | 1993-11-30 | 1995-11-21 | Souryal; Tarek O. | Methods of color coding injectable medications |
| JP2699839B2 (en) | 1993-12-03 | 1998-01-19 | 日本電気株式会社 | Method for manufacturing semiconductor device |
| IE940292A1 (en) | 1994-04-06 | 1995-10-18 | Elan Corp Plc | Biodegradable microcapsules and method for their manufacture |
| JP2865554B2 (en) | 1994-04-08 | 1999-03-08 | セントラル硝子株式会社 | Gas chromatographic analysis of fluoromethyl-1,1,1,3,3,3-hexafluoroisopropyl ether |
| TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| FR2721510B1 (en) | 1994-06-22 | 1996-07-26 | Rhone Poulenc Rorer Sa | Nanoparticles filterable under sterile conditions. |
| US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| WO1996009840A1 (en) | 1994-09-27 | 1996-04-04 | Nycomed Imaging A/S | Contrast agent |
| US5720551A (en) | 1994-10-28 | 1998-02-24 | Shechter; Tal | Forming emulsions |
| SE9403846D0 (en) | 1994-11-09 | 1994-11-09 | Univ Ohio State Res Found | Small particle formation |
| DE4440337A1 (en) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmaceutical nanosuspensions for drug application as systems with increased saturation solubility and dissolution rate |
| US5716642A (en) | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
| PT808154E (en) | 1995-02-06 | 2001-06-29 | Elan Pharma Int Ltd | FORMULATIONS OF COMPOUNDS IN THE FORM OF DISPERSES IN NANOPARTICLES IN OILS OR DIGESTIVE FATTY ACIDS |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
| US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| AU4990696A (en) | 1995-02-24 | 1996-09-11 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
| US5605785A (en) | 1995-03-28 | 1997-02-25 | Eastman Kodak Company | Annealing processes for nanocrystallization of amorphous dispersions |
| ES2170853T3 (en) | 1995-03-28 | 2002-08-16 | Fidia Advanced Biopolymers Srl | NANOSPHERES THAT UNDERSTAND A BIOCOMPATIBLE POLISACARIDE. |
| IE75744B1 (en) | 1995-04-03 | 1997-09-24 | Elan Corp Plc | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| SE9501384D0 (en) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
| US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| FR2735978B1 (en) | 1995-06-30 | 1997-09-19 | Sanofi Sa | PHARMACEUTICAL COMPOSITION OF AMIODARONE FOR PARENTERAL ADMINISTRATION |
| ES2177592T3 (en) | 1995-07-05 | 2002-12-16 | Europ Economic Community | BIOCOMPATIBLE AND BIODEGRADABLE NANOPARTICLES FOR THE ABSORPTION AND ADMINISTRATION OF PROTEINIC MEDICINES. |
| US6143211A (en) | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
| TW487582B (en) | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
| CA2231682A1 (en) | 1995-09-13 | 1997-03-20 | Junzo Seki | Pge1-containing freeze-dried preparation and the production thereof |
| DE19545257A1 (en) | 1995-11-24 | 1997-06-19 | Schering Ag | Process for the production of morphologically uniform microcapsules and microcapsules produced by this process |
| FR2742357B1 (en) | 1995-12-19 | 1998-01-09 | Rhone Poulenc Rorer Sa | STABILIZED AND FILTRABLE NANOPARTICLES UNDER STERILE CONDITIONS |
| US6245349B1 (en) | 1996-02-23 | 2001-06-12 | éLAN CORPORATION PLC | Drug delivery compositions suitable for intravenous injection |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| US5637625A (en) | 1996-03-19 | 1997-06-10 | Research Triangle Pharmaceuticals Ltd. | Propofol microdroplet formulations |
| IL117773A (en) | 1996-04-02 | 2000-10-31 | Pharmos Ltd | Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability |
| US5660858A (en) | 1996-04-03 | 1997-08-26 | Research Triangle Pharmaceuticals | Cyclosporin emulsions |
| AU717764B2 (en) | 1996-05-02 | 2000-03-30 | Taisho Pharmaceutical Co., Ltd. | Suspension of sparingly water-soluble acidic drug |
| DE69737515T2 (en) | 1996-05-07 | 2007-12-06 | Alkermes, Inc., Cambridge | Micro particles |
| JP3391801B2 (en) | 1996-05-20 | 2003-03-31 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Antimicrobial compositions with enhanced bioavailability |
| DE69734988T2 (en) | 1996-08-22 | 2006-09-21 | Jagotec Ag | PREPARATIONS CONTAINING MICROPARTICLES OF WATER-INSOLUBLE SUBSTANCES AND METHOD FOR THE PRODUCTION THEREOF |
| US6344271B1 (en) | 1998-11-06 | 2002-02-05 | Nanoenergy Corporation | Materials and products using nanostructured non-stoichiometric substances |
| DE19637517A1 (en) | 1996-09-13 | 1998-03-19 | Basf Ag | Production of powdered, cold water dispersible carotenoid preparations and the use of the new carotenoid preparations |
| AU4807197A (en) | 1996-10-03 | 1998-04-24 | Paul Bunn | Hydrophilic microparticles and methods to prepare same |
| US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
| DE69727963T2 (en) | 1996-12-17 | 2004-07-22 | Alliant Techsystems Inc., Edina | METHOD FOR CRYSTALLIZING 2,4,6,8,10,12, -HEXANITRO-2,4,6,8,10,12, -HEXAAZATETRAZYKLO- [5.5.0.05.9 0 3.11] -DODECANE BY DEPOSITING |
| US5874111A (en) | 1997-01-07 | 1999-02-23 | Maitra; Amarnath | Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles |
| US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| IT1292142B1 (en) | 1997-06-12 | 1999-01-25 | Maria Rosa Gasco | PHARMACEUTICAL COMPOSITION IN THE FORM OF SOLID LIPID MICROPARTICLES SUITABLE FOR PARENTERAL ADMINISTRATION |
| KR19990001564A (en) | 1997-06-16 | 1999-01-15 | 유충식 | Azole antifungal agents with improved solubility and preparations containing them |
| US6217886B1 (en) | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
| CA2299284C (en) | 1997-08-05 | 2008-07-08 | Mfic Corporation | Multiple stream high pressure mixer/reactor |
| DE19737481A1 (en) | 1997-08-28 | 1999-03-04 | Hoechst Ag | Microparticles containing spherical linear polysaccharides |
| US6281175B1 (en) | 1997-09-23 | 2001-08-28 | Scimed Life Systems, Inc. | Medical emulsion for lubrication and delivery of drugs |
| US5886239A (en) | 1997-11-21 | 1999-03-23 | Baxter International Inc. | Method of preparing monofluoromethyl ethers |
| US6083514A (en) | 1998-01-09 | 2000-07-04 | Abbott Laboratories | Polymethylpentene container for an inhalation anesthetic |
| US6086376A (en) | 1998-01-30 | 2000-07-11 | Rtp Pharma Inc. | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
| EP1067914B1 (en) | 1998-03-30 | 2006-02-22 | Jagotec Ag | Composition and method of preparing microparticles of water-insoluble substances |
| US6337092B1 (en) | 1998-03-30 | 2002-01-08 | Rtp Pharma Inc. | Composition and method of preparing microparticles of water-insoluble substances |
| JP2002511398A (en) | 1998-04-09 | 2002-04-16 | エフ．ホフマン−ラ ロシュ アーゲー | Method for producing (sub) micron sized particles by dissolving in compressed gas and surfactant |
| FR2777193B1 (en) | 1998-04-14 | 2001-06-08 | Coletica | PARTICLE WITH A CHELATING HYDROXAMIC GROUP OF METAL IONS AND THEIR USE IN COSMETICS OR PHARMACY |
| WO1999059535A1 (en) | 1998-05-15 | 1999-11-25 | Unilever Plc | Oral composition comprising capsules |
| US6696019B2 (en) | 1998-06-15 | 2004-02-24 | Bbi Bioseq, Inc. | Rapid cryobaric sterilization and vaccine preparation |
| EP1089714B1 (en) | 1998-06-19 | 2003-03-05 | Skyepharma Canada Inc. | Processes to generate particles of water-insoluble compounds of up to 2000 nm in size |
| FR2780901B1 (en) | 1998-07-09 | 2000-09-29 | Coletica | PARTICLES, IN PARTICULAR MICRO- OR NANOPARTICLES OF CROSSLINKED MONOSACCHARIDES AND OLIGOSACCHARIDES, THEIR PREPARATION METHODS AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS CONTAINING THE SAME |
| US6153225A (en) | 1998-08-13 | 2000-11-28 | Elan Pharma International Limited | Injectable formulations of nanoparticulate naproxen |
| US6238677B1 (en) | 1998-08-18 | 2001-05-29 | The United States Of America As Represented By The Secretary Of Agriculture | Starch microcapsules for delivery of active agents |
| US6165506A (en) | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
| US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| SE9804001D0 (en) | 1998-11-23 | 1998-11-23 | Astra Ab | New process |
| US6365191B1 (en) | 1999-02-17 | 2002-04-02 | Dabur Research Foundation | Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6270806B1 (en) | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| US6267989B1 (en) | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| US6045826A (en) | 1999-04-02 | 2000-04-04 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
| US6632443B2 (en) | 2000-02-23 | 2003-10-14 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
| US6100302A (en) | 1999-04-05 | 2000-08-08 | Baxter International Inc. | Propofol formulation with enhanced microbial characteristics |
| US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| KR100331529B1 (en) | 1999-06-16 | 2002-04-06 | 민경윤 | Composition for Oral Administration of Hardly Soluble Antifungal Agent and Process for the Preparation Thereof |
| US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| IL150524A0 (en) | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| US7338657B2 (en) | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
| NZ522239A (en) | 2000-04-20 | 2004-03-26 | Skyepharma Canada Inc | Improved water-insoluble drug particle process |
| JP3412606B2 (en) | 2000-08-04 | 2003-06-03 | 株式会社島津製作所 | Laser diffraction / scattering particle size distribution analyzer |
| JP2004505761A (en) | 2000-08-15 | 2004-02-26 | ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | Small particles |
| US6635223B2 (en) | 2000-10-25 | 2003-10-21 | Andreas Maerz | Method for inactivating micro-organisms using high pressure processing |
| ES2326209T3 (en) | 2000-10-27 | 2009-10-05 | Baxter Healthcare S.A. | MICRO SPHERES PRODUCTION. |
| US7105176B2 (en) | 2000-11-29 | 2006-09-12 | Basf Aktiengesellschaft | Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds |
| FR2817478A1 (en) | 2000-12-04 | 2002-06-07 | Oreal | Aqueous suspension of nanospheres useful in cosmetic compositions, comprises an amorphous lipophilic active ingredient stabilized with a surfactant |
| DE10063712C1 (en) * | 2000-12-20 | 2002-08-29 | Stiftung A Wegener Inst Polar | Microbiological process for the biosynthesis of the natural blue-violet dyes violacein and deoxyviolacein and their use |
| US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US20040022862A1 (en) | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
| US7037528B2 (en) | 2000-12-22 | 2006-05-02 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
| US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
| US20040256749A1 (en) | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| US20030096013A1 (en) | 2000-12-22 | 2003-05-22 | Jane Werling | Preparation of submicron sized particles with polymorph control |
| US20030072807A1 (en) | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
| US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
| US6951656B2 (en) | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US6310094B1 (en) | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
| TWI277414B (en) * | 2001-01-12 | 2007-04-01 | Baxter Int | Esmolol formulation |
| US20040022861A1 (en) | 2001-01-30 | 2004-02-05 | Williams Robert O. | Process for production of nanoparticles and microparticles by spray freezing into liquid |
| US20030054042A1 (en) | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| IL160570A0 (en) | 2001-09-26 | 2004-07-25 | Baxter Int | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| GB0204772D0 (en) * | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Pharmaceutical dosage forms |
| FR2838969B1 (en) | 2002-04-30 | 2006-05-19 | Ellipse Pharmaceuticals | METHOD FOR HIGH-PRESSURE STERILIZATION OF PHARMACEUTICAL COMPOSITIONS IN THE MICRO OR NANODISPERSEE FORM AND COMPOSITIONS THUS OBTAINED |
| EP1417962A1 (en) | 2002-11-06 | 2004-05-12 | AOP Orphan Pharmaceuticals AG | Method for the manufacture of a medicament comprising esmolol |
| SE0203862L (en) | 2002-12-20 | 2004-04-27 | Tetra Laval Holdings & Finance | Procedure for heat treatment of a package. |
| US20040229901A1 (en) | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| AU2004240640A1 (en) | 2003-05-19 | 2004-12-02 | Baxter International Inc. | Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
| ES2374199T5 (en) | 2003-08-08 | 2015-01-13 | Ono Pharmaceutical Co., Ltd. | Drug for slowing down the heart containing short-acting beta blocker as active ingredient |
| KR20070005617A (en) * | 2004-02-13 | 2007-01-10 | 바이오어베일러빌리티, 아이엔씨. | A microemulsion preparation of high concentration propofol for anesthetic uses |
| EE05278B1 (en) * | 2004-03-23 | 2010-02-15 | As Laser Diagnostic Instruments | Method for Automatic Marking and Subsequent Identification of Liquids |
-
2007
- 2007-05-22 US US11/752,086 patent/US8426467B2/en active Active
- 2007-08-02 KR KR1020097026609A patent/KR20100022991A/en not_active Application Discontinuation
- 2007-08-02 AU AU2007353795A patent/AU2007353795B2/en not_active Ceased
- 2007-08-02 WO PCT/US2007/075069 patent/WO2008143682A1/en active Application Filing
- 2007-08-02 CA CA002686488A patent/CA2686488A1/en not_active Abandoned
- 2007-08-02 JP JP2010509321A patent/JP5825785B2/en not_active Expired - Fee Related
- 2007-08-02 MX MX2009012620A patent/MX2009012620A/en active IP Right Grant
- 2007-08-02 AT AT07813699T patent/ATE512673T1/en active
- 2007-08-02 CN CN2007800530913A patent/CN101678111B/en not_active Expired - Fee Related
- 2007-08-02 BR BRPI0721681-5A patent/BRPI0721681A2/en not_active IP Right Cessation
- 2007-08-02 EP EP07813699A patent/EP2162154B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007353795B2 (en) | 2012-09-13 |
| CN101678111A (en) | 2010-03-24 |
| JP5825785B2 (en) | 2015-12-02 |
| KR20100022991A (en) | 2010-03-03 |
| WO2008143682A1 (en) | 2008-11-27 |
| BRPI0721681A2 (en) | 2014-02-25 |
| EP2162154B1 (en) | 2011-06-15 |
| US8426467B2 (en) | 2013-04-23 |
| ATE512673T1 (en) | 2011-07-15 |
| US20080292558A1 (en) | 2008-11-27 |
| MX2009012620A (en) | 2009-12-11 |
| EP2162154A1 (en) | 2010-03-17 |
| CN101678111B (en) | 2013-01-02 |
| JP2010528001A (en) | 2010-08-19 |
| AU2007353795A1 (en) | 2008-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5778384B2 (en) | Esmolol formulation | |
| CA2410446C (en) | Esmolol formulation | |
| US20150005376A1 (en) | Concentrate esmolol | |
| AU2007353795B2 (en) | Colored esmolol concentrate | |
| AU2008256949B2 (en) | Multi-dose concentrate esmolol with benzyl alcohol | |
| AU2014203121B2 (en) | Concentrate esmolol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20150203 |